Welcome to our dedicated page for Radius Recycling news (Ticker: RDUS), a resource for investors and traders seeking the latest updates and insights on Radius Recycling stock.
Radius Recycling Inc (RDUS) operates North America's premier vertically integrated metals platform, combining recycling operations with auto parts retail and steel production. This page serves as the definitive source for corporate announcements, financial results, and operational developments across all business segments.
Investors and industry professionals will find curated press releases covering quarterly earnings, sustainability initiatives, facility expansions, and strategic partnerships. Our news collection prioritizes official statements about metal recovery innovations, retail network growth, and manufacturing process enhancements.
Key content categories include updates on ferrous/nonferrous market positioning, automotive parts distribution milestones, and steel product innovations. All materials are organized chronologically to help track the company's progress in optimizing its integrated value chain.
Bookmark this page for direct access to primary source materials about RDUS's operational strategies. Check back for real-time updates on how the company maintains leadership through technological investments and supply chain management in the recycling sector.
Radius Health, Inc. (NASDAQ: RDUS) will release its third quarter financial results on November 8, 2021, followed by a conference call at 8:30 a.m. ET. Investors can join via a domestic dial-in at 1 (855) 404-2458 or internationally at 1 (430) 775-1272, using conference ID 9322858. A replay will be available the same day at 11:30 a.m. ET. Radius focuses on unmet medical needs in bone health and oncology, with its lead product, TYMLOS®, approved for high-risk postmenopausal women with osteoporosis.
Radius Health (NASDAQ: RDUS) and Menarini Group announced that their EMERALD study met its primary endpoints, demonstrating significant progression-free survival (PFS) in patients with ER+/HER2- advanced or metastatic breast cancer (mBC). Elacestrant, the first oral selective estrogen receptor degrader (SERD), showed positive results as a monotherapy compared to standard of care. Regulatory submissions are planned in the U.S. and EU for 2022, with data presentation scheduled at the San Antonio Breast Cancer Symposium in December 2021.
Radius Health announced positive topline results from the ATOM study, which evaluated abaloparatide for treating osteoporosis in men. The study met its primary endpoint, showing a significant increase in lumbar spine bone mineral density (BMD) at 12 months (8.5% vs. 1.2% placebo, p-value < 0.0001). Secondary endpoints were also met, reflecting improvements in BMD at 6 months and at the hip and femoral neck after 12 months. The safety profile aligns with previous trials, and a supplemental new drug application (sNDA) is planned for Q1 2022.
Radius Health has updated the TYMLOS® label to clarify its mechanism of action, emphasizing its role in stimulating new bone formation. This change, effective September 20, 2021, aligns with the company's focus on treating postmenopausal women at high risk for fractures. Additionally, the company has welcomed Danielle Holtschlag as the new Head of Sales, bringing over 20 years of experience. Notably, Radius added approximately 3,000 new TYMLOS patients from July to August, reflecting a 13% increase year-over-year.
Radius Health (RDUS) reported Q2 2021 net revenue of $52 million, an increase of 3% year-over-year. The company achieved a significant reduction in adjusted EBITDA losses, reporting ($6) million compared to ($29) million in Q2 2020. However, FY 2021 TYMLOS revenue guidance was lowered from $250 million to $240 million. The company maintains a strong liquidity position with $100 million in cash. Adjusted net loss improved to ($10.5 million) from ($31.1 million) in the same quarter last year.
Radius Health (NASDAQ: RDUS) reported significant growth in new TYMLOS patients, with over 5,000 added in Q2 2021, marking a 40% increase year-over-year. The company expects topline results from the ATOM and wearABLe Phase 3 trials in the second half of 2021 and plans to resubmit regulatory filings in Europe by Q4 2021. Additionally, a pivotal trial for RAD011 targeting Prader-Willi Syndrome is set to begin either in Q4 2021 or Q1 2022. The company aims to demonstrate RAD011's efficacy and safety for FDA approval.
Radius Health (NASDAQ: RDUS) recently revealed FDA Type C meeting minutes that clarify the Phase 2/3 study design for RAD011, a synthetic cannabidiol oral solution aimed at treating Prader-Willi Syndrome (PWS). The company plans to initiate the pivotal SCOUT study by the end of 2021 or early 2022, targeting approximately 200 patients across 30+ global sites, with top-line results expected in late 2024. RAD011 has received Orphan Drug and Fast Track designations, facilitating its regulatory pathway.
Radius Health, Inc. (Nasdaq: RDUS) will release its second quarter financial results on August 5, 2021, and host a conference call at 8:30 a.m. ET to discuss the results and provide updates. Investors can join the conference at 1 (800) 446-1671 or 1 (847) 413-3362 using conference ID 50202646. A replay will be available later that day. Radius is focused on addressing unmet medical needs in endocrinology and has a pipeline including TYMLOS® and investigational drugs for osteoporosis and breast cancer.
